Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2026-02-18 Regulatory Filings
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Percheron to Present at the 2026 AACR Annual Meeting 1
Regulatory Filings Classification · 90% confidence The document is an ASX announcement from Percheron Therapeutics Limited about their upcoming presentation at the American Association of Cancer Research (AACR) Annual Meeting. It discusses the acceptance of an abstract and the planned presentation of clinical trial results at a scientific conference. There is no financial data, no report attached or referenced as being published, and no regulatory filing or certification. The content is an announcement about a future event (presentation) rather than a report or detailed financial disclosure. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Investor Presentation. It is also not a proxy, voting result, or management change announcement. Given the nature of the announcement about a presentation at a scientific meeting, the closest fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2026-02-18 English
Percheron Therapeutics Limited - Corporate Presentation 26 pages 1.9MB
Investor Presentation Classification · 95% confidence The document is an ASX announcement titled 'PERCHERON THERAPEUTICS CORPORATE PRESENTATION' dated 18 February 2026. It is described as an updated non-confidential corporate presentation to be delivered by the CEO at an investment conference. The content includes detailed information about the company's business, product pipeline, market opportunity, and scientific background, typical of an investor presentation. There is no indication that this is a full financial report, audit, or regulatory filing. The document is lengthy (15,000 characters) and contains detailed presentation material rather than just an announcement of a report. Therefore, it fits the category of an Investor Presentation (IP).
2026-02-17 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 605.3KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement titled 'Quarterly Activities Report and Appendix 4C' for the quarter ended 31 December 2025. It contains detailed operational updates, clinical trial progress, and a comprehensive Appendix 4C cash flow report as required by ASX Listing Rule 4.7B. The Appendix 4C is a standard quarterly cash flow report for entities listed on the ASX, including cash flows from operating, investing, and financing activities, as well as payments to related parties. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content includes substantive financial data and analysis for a quarter, which fits the definition of an Interim / Quarterly Report (IR). It is not an initial earnings release (ER) since it contains detailed financial statements and operational commentary. It is not an Annual Report (10-K) or Audit Report (AR), nor is it a simple announcement of report publication (RPA). Therefore, the correct classification is Interim / Quarterly Report (IR). Q4 2025
2026-01-29 English
Change of Director's Interest Notice - Dr Ben Gil Price 3 pages 221.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in shareholding, including the number of shares held before and after the change, the nature of the change, and dates. This is a report of personal share transactions by a company director. The document length is 4003 characters, which is consistent with a detailed director's dealing notice. There is no indication that this is an announcement of a report or a certification. Therefore, the document fits the definition of Director's Dealing (DIRS).
2025-12-29 English
Change of Director's Interest Notice - Dr James Garner 3 pages 221.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details the change in securities held by a director, including the number of shares before and after the change, the nature of the change (shares purchased on market), and dates of the transactions. This is a clear report of personal share transactions by a company director. The document length is 4242 characters, which is consistent with a detailed director's dealing notice. There is no indication of financial results, management discussion, or other report types. Therefore, this document fits the definition of Director's Dealing (DIRS).
2025-12-22 English
Percheron Therapeutics Limited Corporate Presentation 33 pages 1.6MB
Investor Presentation Classification · 95% confidence The document is an ASX announcement titled 'PERCHERON THERAPEUTICS CORPORATE PRESENTATION' dated 5 November 2025. It is described as an updated nonconfidential corporate presentation for shareholders and investors, superseding a previous presentation. The content includes detailed information about the company's pipeline, financial position, management team, market comparisons, and future plans. The document is lengthy (15,000 characters) and contains extensive presentation material, including forward-looking statements, financial data, and strategic information. This matches the definition of an Investor Presentation (IP), which is a detailed presentation for investors focusing on financials, strategy, and market position. It is not a brief announcement, nor a full annual or interim report, nor a regulatory filing or certification. Therefore, the correct classification is Investor Presentation (IP).
2025-11-04 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.